+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 1
Age: 18Years +
All Genders
ID07080242

Phase 1 Open-Label Study Evaluating Safety and Effects of BL-M14D1 in Adults with Advanced or Metastatic Small Cell Lung Cancer and Neuroendocrine Tumors

Led by SystImmune Inc. · Updated on 2026-10-30

120

Participants Needed

31

Research Sites

N/A

Total Duration

AI-Summary

What This Trial Is About

Researchers are evaluating the safety, tolerability, pharmacokinetics, and effectiveness of a drug called BL-M14D1 in adults with locally advanced or metastatic small cell lung cancer and other neuroendocrine tumors. This Phase 1 open-label study aims to understand how this drug behaves in the body and its potential impact on these serious cancers, especially in patients who have already tried standard treatments or cannot receive them. Participants will receive BL-M14D1 through an intravenous infusion on the first day of each 3-week cycle. The study includes multiple groups, including a dose expansion cohort for patients with tumors expressing a specific marker called DLL3. Treatment continues in cycles, and participants are monitored closely for responses and side effects. During the study, participants will undergo regular safety and health assessments, including evaluations of organ function, heart performance, and tumor size using standard criteria. Researchers will track how the drug is processed in the body and its antitumor activity over approximately 18 months. This monitoring helps assess safety, effectiveness, and how well the treatment is tolerated.

CONDITIONS

Brief Title

Evaluating BL-M14D1 in Subjects With Locally Advanced or Metastatic Small Cell Lung Cancer and Neuroendocrine Tumors

Research Team

L

Lien Huzzy

W

Whitney Eakins

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here